AR121570A1 - Compuestos para tratar o inhibir la recidiva de la leucemia mieloide aguda - Google Patents
Compuestos para tratar o inhibir la recidiva de la leucemia mieloide agudaInfo
- Publication number
- AR121570A1 AR121570A1 ARP210100645A ARP210100645A AR121570A1 AR 121570 A1 AR121570 A1 AR 121570A1 AR P210100645 A ARP210100645 A AR P210100645A AR P210100645 A ARP210100645 A AR P210100645A AR 121570 A1 AR121570 A1 AR 121570A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halo
- alkoxy
- compound
- acyloxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 title 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 125000004423 acyloxy group Chemical group 0.000 abstract 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- -1 phenyloxy Chemical group 0.000 abstract 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1), donde cada Q, Y y Z se seleccionan independientemente entre N y C, y X es N o C-Rᵃ; con la condición de que al menos uno de Q, X, Y y Z sea N, y cada enlace discontinuo es independientemente un enlace simple o doble, de modo que el biciclo que forman es un heteroarilo; R¹ se selecciona entre alquilo, alquenilo, alquinilo, amino, acilamino, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, arilo, arilalquilo, heteroarilo y heteroaralquilo; o a) W es N, R² está ausente, y A¹ y A² son cada uno CH₂; b) W es C, R² se selecciona entre H, halo, CN, alquilo, alcoxi, hidroxi, aciloxi y amino, y A¹ y A² se seleccionan cada uno independientemente entre CH₂ y O; o c) W es C, y R¹ y R² se toman juntos para formar un =CH₂-amido, cicloalquilo y heterociclilo, y A¹ y A² se seleccionan cada uno independientemente entre CH₂ y O; Rᵃ se selecciona entre H, halo, CN y alquilo; R⁹ se selecciona entre H, halo, alquilo, alcoxi, hidroxi, aciloxi y amino; R¹⁰ es H o alcoxi, R¹¹ es ariloxi, heteroariloxi, arilalquilo, alcoxicarbonilo, ureido o -C(O)-arilo; y R¹² se selecciona entre H, halo, CN, alquilo, alcoxi, hidroxi y aciloxi; con la condición de que el compuesto de fórmula (1) no sea un compuesto del grupo de fórmulas (2); y si W es C, R², R⁹ y R¹² son cada uno hidrógeno, y R¹¹ es feniloxi no sustituido, entonces R¹ no es -NHCH₂OH, -NHCH₂COOH, -NHCH₂CONH₂, -NHCH₂CH₂NH₂, -NH(CH₂)₂N(Me)₂, -NHCH₂-piridinilo, -NHCO-piridilo, -C(O)OEt, -NH-tetrahidropirano, -NHCH₂-pirrolidinilo, -NH(CH₂)₃-imidazolilo, -NH-pirrolidinonilo, o un compuesto del grupo de fórmula (3), donde R¹³ se selecciona entre H, etilo, isopropilo, t-butilo, -CH₂OCH₃, -CH₂CH₂OH y -CH₂CH₂OCH₃; y si W es N, R⁹ y R¹² son cada uno hidrógeno, y R¹¹ es feniloxi no sustituido, entonces R¹ no es piperidinilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/079464 WO2021184154A1 (en) | 2020-03-16 | 2020-03-16 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121570A1 true AR121570A1 (es) | 2022-06-15 |
Family
ID=77767943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100645A AR121570A1 (es) | 2020-03-16 | 2021-03-12 | Compuestos para tratar o inhibir la recidiva de la leucemia mieloide aguda |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11963960B2 (es) |
| EP (1) | EP4121430A4 (es) |
| JP (1) | JP2023518035A (es) |
| KR (1) | KR20220154164A (es) |
| CN (1) | CN115298180A (es) |
| AR (1) | AR121570A1 (es) |
| AU (1) | AU2020436612A1 (es) |
| BR (1) | BR112022018345A2 (es) |
| CA (1) | CA3168988A1 (es) |
| IL (1) | IL296296A (es) |
| MX (1) | MX2022011407A (es) |
| PE (1) | PE20230461A1 (es) |
| TW (1) | TW202200583A (es) |
| WO (2) | WO2021184154A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021184154A1 (en) | 2020-03-16 | 2021-09-23 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| IL297979A (en) | 2020-05-08 | 2023-01-01 | Halia Therapeutics Inc | Inhibitors of nek7 kinase |
| CN113861179A (zh) * | 2021-10-22 | 2021-12-31 | 上海应用技术大学 | 一种新型flt3激酶抑制剂及其合成与应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0970084T3 (da) * | 1997-03-19 | 2003-09-29 | Abbott Gmbh & Co Kg | Pyrrolo[2,3-d]pyrimidiner og deres anvendelse som inhibitorer for tyrosinkinase |
| US6713474B2 (en) * | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| DK1212327T3 (da) * | 1999-09-17 | 2003-12-15 | Abbott Gmbh & Co Kg | Pyrazolopyrimidiner som terapeutiske midler |
| MXPA03008560A (es) * | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| US20060025383A1 (en) * | 2004-02-03 | 2006-02-02 | Neil Wishart | Aminobenzoxazoles as therapeutic agents |
| EP2954900A1 (en) | 2007-03-28 | 2015-12-16 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| EP2878601B1 (en) * | 2012-07-27 | 2018-03-28 | Riken | Agent for treating or controlling recurrence of acute myelogenous leukemia |
| USRE48175E1 (en) * | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| CN105481862B (zh) | 2015-01-21 | 2018-08-21 | 中国科学院合肥物质科学研究院 | Flt3激酶的新型抑制剂及其用途 |
| GB201508747D0 (en) | 2015-05-21 | 2015-07-01 | Univ Edinburgh | Compounds |
| WO2018052120A1 (en) * | 2016-09-15 | 2018-03-22 | Riken | A hck inhibitor and a bcl-2 inhibitor for treating acute myeloid leukemia |
| TWI762939B (zh) | 2019-05-31 | 2022-05-01 | 大陸商海思科醫藥集團股份有限公司 | Btk抑制劑環衍生物及其製備方法和藥學上的應用 |
| CA3143508A1 (en) | 2019-06-24 | 2020-12-30 | Dana-Farber Cancer Institute, Inc. | Hck degraders and uses thereof |
| KR20220098732A (ko) | 2019-10-08 | 2022-07-12 | 다나-파버 캔서 인스티튜트 인크. | 요법, 특히 myd88 돌연변이된 질환에 사용하기 위한 hck 억제제로서의 피라졸로피리미딘 유도체 |
| WO2021184154A1 (en) | 2020-03-16 | 2021-09-23 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
-
2020
- 2020-03-16 WO PCT/CN2020/079464 patent/WO2021184154A1/en active Application Filing
- 2020-03-16 AU AU2020436612A patent/AU2020436612A1/en active Pending
-
2021
- 2021-03-12 AR ARP210100645A patent/AR121570A1/es unknown
- 2021-03-15 EP EP21772015.0A patent/EP4121430A4/en active Pending
- 2021-03-15 PE PE2022001990A patent/PE20230461A1/es unknown
- 2021-03-15 BR BR112022018345A patent/BR112022018345A2/pt not_active Application Discontinuation
- 2021-03-15 JP JP2022555625A patent/JP2023518035A/ja active Pending
- 2021-03-15 CN CN202180016180.0A patent/CN115298180A/zh active Pending
- 2021-03-15 MX MX2022011407A patent/MX2022011407A/es unknown
- 2021-03-15 IL IL296296A patent/IL296296A/en unknown
- 2021-03-15 WO PCT/US2021/022322 patent/WO2021188417A1/en unknown
- 2021-03-15 KR KR1020227035324A patent/KR20220154164A/ko unknown
- 2021-03-15 CA CA3168988A patent/CA3168988A1/en active Pending
- 2021-03-15 US US17/201,827 patent/US11963960B2/en active Active
- 2021-03-16 TW TW110109254A patent/TW202200583A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20230461A1 (es) | 2023-03-14 |
| KR20220154164A (ko) | 2022-11-21 |
| US11963960B2 (en) | 2024-04-23 |
| CA3168988A1 (en) | 2021-09-23 |
| AU2020436612A1 (en) | 2022-09-01 |
| EP4121430A1 (en) | 2023-01-25 |
| US20210299128A1 (en) | 2021-09-30 |
| MX2022011407A (es) | 2022-10-13 |
| WO2021184154A1 (en) | 2021-09-23 |
| CN115298180A (zh) | 2022-11-04 |
| EP4121430A4 (en) | 2024-04-17 |
| IL296296A (en) | 2022-11-01 |
| JP2023518035A (ja) | 2023-04-27 |
| TW202200583A (zh) | 2022-01-01 |
| BR112022018345A2 (pt) | 2022-11-08 |
| WO2021188417A1 (en) | 2021-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR121570A1 (es) | Compuestos para tratar o inhibir la recidiva de la leucemia mieloide aguda | |
| EA202190342A1 (ru) | Гетеробициклические соединения для ингибирования активности shp2 | |
| AR121044A1 (es) | Inhibidores de egfr | |
| AR117101A1 (es) | Síntesis mejorada del intermedio clave del compuesto inhibidor de g12c de kras | |
| PE20221253A1 (es) | Inhibidores de pequenas moleculas de mutante g12c de kras | |
| AR120338A1 (es) | Piridazinonas como inhibidores de parp7 | |
| ES2571327T3 (es) | Composiciones plaguicidas | |
| ECSP055987A (es) | Derivados de heteroarilcarbamoilbenceno | |
| CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
| ES2590504T3 (es) | N-ciclilamidas como nematicidas | |
| CO4900063A1 (es) | Piridinas substituidas como inhibidores selectivos de ciclo- oxi-genasa2 | |
| CO6321244A2 (es) | Pirrolopiridinas como inhibidores de cinasa | |
| AR094704A1 (es) | Compuestos y composiciones como degradantes selectivos del receptor de estrógeno | |
| CO5680430A2 (es) | Derivados de 1-benzol-piperazina como inhibidores de la captacion de glicina para el ratamiento de psicosis | |
| AR075510A1 (es) | Inhibidores del virus de la hepatitis c | |
| EA201600403A1 (ru) | N-ацилиминогетероциклические соединения | |
| AR064355A1 (es) | Herbicidas derivados de isoxazol | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| AR109868A1 (es) | Derivados heterocíclicos activos como plaguicidas con sustituyentes con azufre e hidroxilamina | |
| AR090868A1 (es) | Composiciones plaguicidas y procesos relacionados con ellas | |
| DOP2020000221A (es) | Derivado policíclico de carbamoilpiridona | |
| HUP0401784A2 (hu) | Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények | |
| AR060621A1 (es) | Compuestos triarilicos y sus derivados | |
| DOP2020000222A (es) | Derivado policiclico de piridona | |
| CY1124908T1 (el) | Παραγωγο μορφινανης |